Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines

Molecular Cancer Therapeutics

Volumn 4, Issue 8, 2005, Pages 1222-1230

  García Morales, Pilar ^a   Gómez Martínez, Angeles ^a   Carrato, Alfredo ^a,b   Martínez Lacaci, Isabel ^a   Barberá, Víctor M ^b   Soto, José L ^b   Carrasco García, Estefanía ^a   Menéndez Gutierrez, María P ^a   Castro Galache, María D ^a   Ferragut, José A ^a   Saceda, Miguel ^a,b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CASPASE; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 8; CASPASE 9; DNA FRAGMENT; HISTONE DEACETYLASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE OMI; TRICHOSTATIN A; UCF 101; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL NUCLEUS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME MECHANISM; HUMAN; HUMAN CELL; MITOCHONDRION; MULTIDRUG RESISTANCE; PANCREAS ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SECRETION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE, TUMOR; ENZYME INHIBITORS; FLAVOPROTEINS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MEMBRANE PROTEINS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SERINE ENDOPEPTIDASES;

EID: 23844486708     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0186     Document Type: Article

References (51)

1. Blaszkowsky L. Treatment of advanced and metastatic pancreatic cancer. Front Biosci 1998;3:214-25.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
3. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′, 2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
4. Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-5.
5. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15: 2403-13.
6. Okusaka T, Kosuge T. Systemic chemotherapy for pancreatic cancer. Pancreas 2004;28:301-4.
7. Roche Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002;20:1182-91.
8. Xing HR, Cordon-Cardo C, Deng X, et al. Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat Med 2003;9:1266-8.
9. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995;55:3810-5.
10. Takeuchi M, Shichinohe T, Senmaru N, et al. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther 2000;7: 518-26.
11. Shichinohe T, Senmaru N, Furuuchi K, et al. Suppression of pancreatic cancer by the dominant negative ras mutant. J Surg Res 1996;66:125-30.
12. Kijima H, Scanlon KJ. Ribozyme as an approach for growth suppression of human pancreatic cancer. Mol Biotechnol 2000;14:59-72.
13. Ghaneh P, Greenhalf W, Humphreys M, et al. Adenovirus-mediated transfer of p53 and p16 (INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001;8:199-208.
14. Kimura M, Tagawa M, Takenaga K, et al. Inability to induce the alteration of tumorigenicity and chemosensitivity of p53-null human pancreatic carcinoma cells after the transduction of wild-type p53 gene. Anticancer Res 1997;17:879-83.
15. Kawaguchi Y, Takebayashi H, Kakizuka A, Arii S, Kato M, Imamura M. Expression of Fas-estrogen receptor fusion protein induces cell death in pancreatic cancer cell lines. Cancer Lett 1997;116:53-9.
16. Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, Parekh D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996;224:405-17.
17. Rosenfeld M, Vickers S, Raben D. Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. Ann Surg 1997;225:609-20.
18. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52.
19. Brownell JE, Zhou J, Ranalli T, et al. Tetrahymena histone acetyltransferase A: a homology to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996;84:843-51.
20. Ayer DE. Histone deacetylases: transcriptional repression with SINers and NuRDs. Trends Cell Biol 1999;9:193-8.
21. Kwon SH, Ahn SH, Kim YK, et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression on human acute promyelocytic leukaemia cells. J Biol Chem 2002; 277:2073-80.
22. Th'ng JP, Histone modifications and apoptosis: cause or consequence? Biochem Cell Biol 2001;79:305-11.
23. Glick RD, Swendeman SL, Coffey DC, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999;59:4392-9.
24. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 1998;95:3003-7.
25. Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltrasnferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 2002;86:41-65.
26. Minucci S, Horn V, Bhattacharyya N, et al. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc Natl Aced Sci U S A 1997;94:11295-300.
27. Luo J, Su F, Chen D, Shiloh D, Gu W. Deacetylation of p53 modulates its effects on cell growth and apoptosis. Nature 2000;408: 377-81.
28. Castro-Galache MD, Ferragut JA, Barbera VM, et al. Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. Int J Cancer 2003;104:579-86.
29. Moore PS, Sipos B, Orlandini S, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Virchows Arch 2001;439:798-802.
30. Susin SA, Daugas E, Ravagnan L, et al. Two distinct pathways leading to nuclear apoptosis. J Exp Mad 2000;192:571-9.
31. Sarin A, Nakajima H, Henkart PA. A protease-dependent TCR-induced death pathway in mature lymphocytes. J Immunol 1995;154: 5806-12.
32. Egger L, Schneider J, Rheme C, Tapernoux M, Hacki J, Borner C. Serine proteases mediate apoptosis-like cell death and phagocytosis under caspase-inhibiting conditions. Cell Death Differ 2003;10: 1188-203.
33. Cilenti L, Lee Y, Hess S, et al. Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2. J Biol Chem 2003; 278:11489-94.
34. Henderson C, Mizzau M, Paroni G, Maestro R, Scheneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003;278: 12579-89.
35. Selznick LA, Zheng TS, Flavell RA, Rakic P, Roth KA. Amyloid β-induced neuronal death is bax-dependent but caspase-independent. J Neuropathol Exp Neurol 2000;59:271-9.
36. Kouraklis G, Theocharis S. Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem Anti-Canc Agents 2002;2:477-84.
37. Rosato RR, Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2003;2:30-7.
38. Ruefli AA, Bernhard D, Tainton KM, Koefler R, Smyth MJ, Johnstone RW. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 2002;99:292-8.
39. Tsurutani J, Soda H, Oka M, et al. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Int J Cancer 2003;104:238-42.
40. Aron JL, Parthun MR, Marcucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukaemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003;102:652-8.
41. Herold C, Ganslmayer M, Ocker M, et al. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002;36:233-40.
42. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
43. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101:4055-62.
44. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001;98:10833-8.
45. Daugas E, Susin SA, Zamzami N, et al. Mitochondrio-nuclear redistribution of AIF in apoptosis and necrosis. FASEB J 2000;14:729-39.
46. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose)polymerase-1-dependent cell death by apoptosis-inclucing factor. Science 2002;297:259-63.
47. Kim SG, Ravi G, Hoffmann C, et al. p53-Independent induction of FAS and apoptosis in leukemic cells by an adenosine derivative, CI-IB-MECA. Biochem Pharmacol 2002;63:871-80.
48. Mann CL, Hughes FM, Cidlowski JA. Delination of the signalling pathways involved in glucocorticoid-induced and spontaneous apoptosis of rat thymocytes. Endocrinology 2000;141:528-38.
49. Donadelli M, Costanzo C, Faggioli L, et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003;38:59-69.
50. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol 2003;3:344-51.
51. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 1999;96:4592-7.